Kathryn Andrews is the New CFO and Company Secretary of Genetic Technologies

Genetic Technologies Limited (ASX: GTG, NASDAQ: GENE, OTC: GNTLF), a global leader in genomics-based testing, strengthens its leadership team with the appointment of Kathryn Andrews as Chief Financial Officer and Company Secretary, effective immediately.

CEO Simon Morriss expressed enthusiasm about Andrews’ appointment, highlighting her extensive industry experience and proficiency in both ASX and Nasdaq environments. Morriss expressed confidence in Andrews’ ability to significantly contribute to the company’s growth trajectory and strategic objectives.

Bringing a wealth of experience in the biotechnology sector, Andrews is a seasoned executive with a notable track record in ASX and Nasdaq-listed companies. Her most recent role as CFO at Alterity Therapeutics Ltd showcased her adeptness in financial stewardship within the biotechnology landscape.

Andrews’ earlier tenure with The CFO Solution, specializing in outsourced CFO services for listed public companies, further underscores her expertise in navigating the complexities of the biotechnology sector. Previously, Andrews served as CFO and Company Secretary at Antisense Therapeutics Ltd, demonstrating her multifaceted leadership capabilities within the industry.

Have you read?
Report: Countries with the highest rates of Dementia, 2024.
Report: Countries with the Highest Rates of Lung Cancer, 2024.
Report: These Are The Countries with Universal Health Coverage Programs, 2024.
Revealed: These Are The Countries with the Highest Death Rates, 2024.
Revealed: The Healthiest (and Unhealthiest) Countries in the World, 2024.